Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen receives CHMP backing for new Velcade applications

Janssen receives CHMP backing for new Velcade applications

4th July 2013

Janssen has received a recommendation from Europe's Committee for Medical Products for Human Use (CHMP) for the use of its multiple myeloma drug Velcade in new indications.

The first recommendation from the European Medicines Agency committee endorses Velcade as a retreatment option for adult patients who have previously responded to therapy with the same medicine.

Meanwhile, the CHMP also backed the drug for use as an induction therapy, in combination with dexamethasone or dexamethasone and thalidomide, among previously untreated patients who are eligible for high-dose chemotherapy with haematological stem cell transplantation.

Data from clinical trials has supported the efficacy of Velcade in both of these indications, with a final decision on the matter expected from the European Commission in September 2013.

This comes after Janssen became the latest healthcare company to join the precompetitive consortium of the Multiple Myeloma Research Foundation last month, a move that will allow the company to contribute to collaborative research in this field.ADNFCR-8000103-ID-801607967-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.